Evidence map›Paper›PMID 37792237›Full record

ArticleTargeted oncology2023

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.

Xiuning Le, Eric Nadler, Daniel B Costa, John Victor Heymach

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Targeted oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-NaïveJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  2. Lung cancer withTranslational lung cancer research · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Xiuning LeThe University of Texas MD Anderson Cancer Center, Houston, TX, USA. xle1@mdanderson.org.
Eric NadlerBaylor University Medical Center, Dallas, TX, USA.
Daniel B CostaDivision of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
John Victor HeymachThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USBaylor University Medical Center · USHarvard University · US

Funding

Unmet needs for specific subsets of EGFR mutated lung cancerR37CA218707 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI COSTA, DANIEL BOTELHO · 2018 to 2024
$2.8M
NCI NIH HHS R37 CA218707
6 · The paper itself

Abstract

Supplementary file1 (MP4 21169 KB).

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsErbB ReceptorsHumansMutationProtein Kinase InhibitorsTyrosine Kinase InhibitorsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsTyrosine Kinase Inhibitors

Identifiers

PMID37792237
PMCPMC10663258
OpenAlexW4387324531

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.